Advanced glycation end products, oxidant stress and vascular lesions

European Journal of Clinical Investigation

Volumn 27, Issue 2, 1997, Pages 97-108

  Chappey, O ^a   Dosquet, C ^a   Wautier, M P ^a   Wautier, J L ^a,b  

^a INSERM   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

atherosclerosis; endothelial cells; glycation; monocytes; oxidant stress

Indexed keywords

ATHEROSCLEROSIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; GLYCATION; HUMAN; OXIDATION; PRIORITY JOURNAL; REVIEW; STRESS; VASCULAR LESION;

EID: 0031048334     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1997.710624.x     Document Type: Review

References (107)

1. King GL, Shiba T, Oliver J, Inoguchi T, Bursell SE. Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus. Annu Rev Med 1994;45:179-88.
2. Bunn HF, Higgins PJ. Reaction of monosaccharides with proteins: possible evolutionary significance. Science 1981;213:222-4.
3. Knecht KG, Feather MS, Baynes JW. Detection of 3-deoxyfructose and 3-deoxyglycanosone in human urine and plasma: evidence for intermediate stages of Maillard reaction in vivo. Arch Biochem Biophys 1992;294:130-1.
4. Fu MX, Knecht KJ, Thorpe R et al. Role of oxygen in cross linking and chemical modification of collagen by glucose. Diabetes 1992;41:42-8.
5. Hunt JV, Bottoms MA, Mitchinson MJ. Oxidative alterations in the experimental glycation model of diabetes mellitus are due to protein-glucose adduct oxidation. Biochem J 1993;291:529-35.
6. Maillard LC. Action des acides aminés sur les sucres. Formation des mélanoïds par voie méthodique. Compte Rendu Acad Sci (France), 1952;154:66-8.
7. Hunt JV, Dean RT, Wolf SP. Hydroxy radical production and antioxidative glycosylation: glucosyl autooxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. Biochemistry 1988;256:205-12.
8. Ahmed MU, Thorpe SR, Baynes JW. Identification of W-carboxymethyl-lysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986;261:4889-94.
9. Tongor S, Ulrich PC, Bencsath FA, Cerami A. Aging of proteins: isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. Proc Natl Acad Sci USA 1984;81:2684-8.
10. Palinski W, Koschinsky T, Butler SW et al. Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of englycemic rabbits. Arterioscl Thromb Vasc Biol 1995;15:571-82.
11. Famar J, Ulrich P, Cerami A. Novel pyrroles from sulfite-inhibited Maillard reactions: insight into the mechanism of inhibition. J Org Chem, 1988;53:2346-9.
12. Nsoroge FG, Fernandes AA, Monnier VM. Mechanism of formation of the putative advanced glycosylation end product and protein cross-link 2-(2-furayl)-4(5)-(2-furamyl)-1H-imidazole. J Biol Chem 1988;263:10646-52.
13. Makita Z, Vlassara H, Cerami A, Bucala R. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992;267:5133-8.
14. 2-(1-carboxyethyl)guanine (CEG) as a guanine advanced glycosylation end product. Biochemistry 1995;34:648-55.
15. Brownlee M, Vlassara H, Kooney T, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross linking. Science 1986;232:1629-32.
16. Chen HJ, Cerami A. Mechanism of inhibition of advanced glycosylation by aminoguanidine in vitro. J Carbohydr Chem 1993;12:731-42.
17. Corbett JA, Tilton RG, Chang K et al. Aminoguanidine, a novel inhibition of nitric oxide formation, prevents diabetic vascular dysfunctions. Diabetes 1992;41:552-6.
18. Menni T, Gugliucci A, Stahl AJC. Polyclonal immunoglobulin M: location of glycation sites. Clin Chim Acta 1992;213:23-35.
19. Zoppe F, Mosca A, Granata S, Montalbetti N. Glycated proteins in serum: effect of their relative proportions on their alkaline reducing activity in the fructosomine test. Clin Chem 1987; 33:1895-7.
20. Iberg N, Fluciger R. Non enzymatic glycosylation of albumin in vivo. J Biol Chem 1986;261:13542-5.
21. Williams SK, Devenny JJ, Bitensky MW. Micropinocytic ingestion of glycosylated albumin by isolated microvessels: possible role in pathogenesis of diabetic microangiopathy. Proc Natl Acad Sci USA 1981;78:2393-9.
22. Ducrocq R, Bachour M, Belkhodja R et al. Evidence for non-enzymatic glycation of antithrombin III in diabetic patients. Clin Chem 1985;31:338-9.
23. Brownlee M, Vlassara H, Cerami A. Non enzymatic glycosylation reduces the susceptibility of fibrine to degradation by plasmin. Diabetes 1983;32:680-4.
24. Mahley RW, Innerarity TL, Weisgraber KH, Oh SY. Altered metabolism (in vivo and in vitro) of plasma lipoproteins after selective chemical modification of lysine residues of the apoprotein B. J Clin Invest 1979;64:743-50.
25. Bucala R, Makita Z, Koscjinsky T, Cerami A, Vlassara H. Lipid advanced glycation pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993;90:6434-8.
26. Steinbrecher U, Witztum JL. Glycosylation of low-density lipoproteins on a extent comparable to that seen in diabetes shows their catabolism. Diabetes 1984;33:130-4.
27. Hoff HF, Whitaker TE, O'Neil J. Oxidation of low density lipoprotein leads to particle aggregation and altered macrophage recognition. J Biol Chem 1992;267:602-9.
28. Curtiss LK, Witztum JL. A novel method for generating region specific monoclonal antibodies to modify proteins: application to the identification of human glycosylated low density lipoproteins. J Clin Invest 1983;72:1427-38.
29. Witzum JL, Steinbrecher UP, Kesaniemiy A et al. Autoantibodies to glycosylated proteins in the plasma of patients with diabetes mellitus. Proc Natl Acad Sci USA 1984;81:3204-8.
30. Dueil PB, Oram JF, Bierman EL. Non-enzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux. Diabetes 1991;40:377-84.
31. Yamamoto M, Ranganathan S, Koitke A. Metabolism of glycosylated very-low-density lipoproteins in human skin tibroblasts. Biochem Biophys Acta 1986;875:410-13.
32. Musliner TA, Herbert PN, Church EC. Activation of lipoprotein lipase hyperactive and acetylated peptide of apo-CII. Biochim Biophys Acta 1979;573:501-9.
33. Vlassara H, Brownlee M, Cerami A. High-affinity receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci USA 1985;82:5588-92.
34. Gilcrease MZ, Hoover RL. Activated human monocytes exhibit receptor-mediated adhesion to a non-enzymatically glycosylated protein substrate. Diabetologia 1990;33:329-33.
35. Imani F, Horii Y, Suthanthiran M et al. Advanced glycosylation end product-specific receptors on human and rat T-lymphocytes mediates synthesis of interferon gamma: role in tissue remodeling. J Exp Med 1993;178:2165-72.
36. Radoff S, Vlassara H, Cerami A. Characterization of a solubilized cell surface binding protein on macrophages specific for proteins modified non-enzymatically by advanced glycosylation endproducts. Arch Biochem Biophys 1988;263:418-23.
37. Yang Z, Makita Z, Horii Y et al. Two novel rat liver membrane proteins that bind advanced glycosylation enproducts: relationship to macrophage receptor glucose-modified proteins. J Exp Med 1991;174:515-4.
38. Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodeling and diabetic nephropathy. J Exp Med 1991;174:931-9.
39. Schmidt AM, Vianna M, Gerlach M et al. Isolation and characterization of binding proteins for advanced glycosylation endproducts from lung tissue which are present on the endothelial cell surface. J Biol Chem 1992;267:14987-97.
40. Schmidt AM, Mora R, Cao R et al. The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. J Biol Chem 1994;269:9882-8.
41. Neeper M, Schmidt AM, Brett J et al. Cloning expression of RAGE: a cell surface receptor for advanced glycosylation endproducts of proteins. J Biol Chem 1992;267:14998-15004.
42. Sugaya K, Fukagawa T, Matsumoto KI et al. Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation endproducts, BPX2 homeobox gene and a Notch homolog, human counterpart of mouse mammary tumor gene int-3. Genomics 1994;23:408-19.
43. Hori O, Brett J, Slattery T et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. J Biol Chem 1995;270:25752-61.
44. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 1994; 14:1521-8.
45. Ming, Li YX, Tan A, Vlassara H. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycatin-modified proteins to a conserved motif. Nature Med 1995;10:1057-61.
46. Bunn HF, Shapiro R, McManus M et al. Structural heterogeneity of human hemoglobin A due to nonenzymatic glycosylation. J Biol Chem 1979;254:3892-8.
47. McDonald MJ, Shapiro R, Bleichman M et al. Glycosylated minor components of human adult hemoglobin. J Biol Chem 1978;253:2327-32.
48. Ratnaikes S, Blake D, Shevenan P, Enzymatic glycation may decrease activity of erythrocyte S-aminolevulinate dehydratase in diabetes mellitus. Clin Chem 1987;33:1807-10.
49. Argawak KC, Parks RE, Widenss JA et al. Non enzymatic glycosylation of erythrocytic proteins in normal and diabetic subjects, enzyme of nucleoside and nucleotide metabolism. Diabetes 1985;34:251-5.
50. Miller JA, Gravallese E, Bunn HF. Nonenzymatic glycosylation of erythrocyte membrane proteins: relevance to diabetes. J Clin Invest 1980;65:896-901.
51. Bryszewska M, Szosland K. Association between glycation of erythrocyte membrane proteins and membrane fluidity. Ann Clin Res 1988;21:49-51.
52. Watala C, Zawodniak M, Bryszewska M, Novak S. Nonenzymatic protien glycosylation I. Lowered erythrocyte membrane fluidity in juvenile diabetes. Ann Clin Res 1985;17:327-30.
53. McMillan DE, Utterback NG, La Puma J. Reduced erythrocyte deformability in diabetes. Diabetes 1978;27:895-901.
54. Inaba M, Maede Y. Correlation between 4.1a/4.1b ratio and erythrocyte life span. Biochem Biophys Acta 1988;944:256-64.
55. Wautier JL, Paton CR, Wautier MP et al. Increased adhesion of erythrocytes to endothelial cells in diabetes mellitus and their relation to the vascular complications. N Engl J Med 1981; 305:237-42.
56. Wautier JL, Wautier MP, Schmidt AM et al. Advanced glycation end products (AGE) on the surface of diabetic red cells bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci USA 1994;91:7742-6.
57. Vlassara H. Recent progress on the biologic and clinical significance of advanced glycation end products. J Lab Clin Med 1994;124:19-30.
58. Kirstein M, Brett J, Radoff S, Ogana S, Stern D, Vlassara H. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of PDGF: role in vascular disease of diabetes and aging. Proc Natl Acad Sci USA 1990; 87:9010-4.
59. Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 1993;92:2155-68.
60. Vlassara H, Fuh H, Makita Z, Krungkari S, Cerami A, Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci USA 1992; 89: 12043-7.
61. Vlassara H, Brownlee M, Manogue KR, Dinarello C, Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1988;240:1546-8.
62. Kirstein M, Aston C, Hintz R, Vlassara H. Receptor specific induction of insulin-like growth factor I (IGF-I) in human monocytes by advanced glycosylation end products-modified proteins. J Clin Invest 1992;90:439-46.
63. Vlassara H, Brownlee M, Cerami A. Specific macrophage receptor activity for advanced glycation end products inversely correlates with insulin levels in vivo. Diabetes 1988;37:456-61.
64. Vlassara H, Moldawer L, Chan B. Macrophage/monocyte receptor for non enzymatically glycosylated proteins is up regulated by cachectin/tumor necrosis factor. J Clin Invest 1989;84:1813-20.
65. Cohen I, Burk DL, Fullerton R, Veis A, Green D. Nonenzymatic glycation of platelet proteins in diabetic patients. Semin Thromb Hemost 1991;17:426-32.
66. Strano A, Davi G, Patrono C. In vivo platelet activation in diabetes mellitus. Semin Thromb Hemost 1991;17:422-5.
67. Ritthaler U, Deng Y, Zhang Y et al. Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am J Pathol 1995;146:688-94.
68. Cagliero E, Roth T, Roy S, Lorenzi M. Characteristics and mechanisms of high-glucose-induced overexpression of basement membrane components in cultured human endothelial cells. Diabetes 1991;40:102-10.
69. Brownlee M, Cerami A, Vlassara H. Advanced glycation end products in tissue and the biochemical basis of diabetic complication. N Engl J Med 1988;318:1315-21.
70. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 1992;15:1835-43.
71. Charonis AS, Reger LA, Dege JE et al. Laminin alterations after in vitro nonenzymatic glycosylation. Diabetes 1990;39:807-14.
72. 4 proteoglycan by heparin from glomeruli of streptozotocin-induced diabetic rats. Diabetes 1989;38:130-9.
73. Rupslathi E, Yamaguchi Y. Proteoglycans as modulators of growth factor activities. Cell 1991;64:867-9.
74. Haitoglou CS, Tsilibary EC, Brownlee M, Charonis AS. Altered cellular interactions between endothelial cells and nonenzymatically glycosylated laminin/type IV collagen. J Biol Chem 1992;267:12404-7.
75. Brownlee M, Vlassara H, Cerami A. Non enzymatic glycosylation products on collagen covalently trap low density lipoprotein. Diabetes 1985;34:938-41.
76. Huijberts MSP, Wolfenbutel BHR, Struijker R et al. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J Clin Invest 1993;92:1407-11.
77. Schmidt AM, Hasu M, Popov D et al. Receptor for AGEs has a central role in vessel wall interactions and gene activation in response to AGE proteins. Proc Natl Acad Sci USA 1994; 91:8807-11.
78. Zoukourian C, Wautier MP, Chappey O et al Endothelial cell dysfunction secondary to the adhesion of diabetic erythrocytes, modulation by Iloprost. Int Angiol 1996;15:195-200.
79. Esposito C, Gerlach H, Brett J, Stern D, Vlassara H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 1989;170:1387-407.
80. Bucala R, Tracey KJ, Cerami A. Advanced glycation end products quench nitric oxide and mediate defective endothelium dependent vasodilatation in experimental diabetes. J Clin Invest 1991;87: 432-8.
81. Hogan M, Cerami A, Bucala R. Advanced glycosylation end products block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J Clin Invest 1992;90:1110-5.
82. Tezuka M, Koyama N, Morisaki N et al. Angiogenic effects of advanced glycation end products of the Maillard reaction on cultured human umbilical cord vein endothelial cells. Biochem Biophys Res Commun 1993;193:674-80.
83. Cagliero E, Maiello M, Boeri D, Roy S, Lorenzi M. Increased expression of basement membrane components in human endothelial cells cultured in high glucose. J Clin Invest 1988; 82:735-38.
84. Roy S, Sala R, Cagliero E, Lorenzi M. Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proc Natl Acad Sci USA 1990;87:404-8.
85. Ames B, Shigenaga MK, Hagen M. Oxidants, antioxidants and the degenerative disease of aging. Proc Natl Acad Sci USA 1993;90: 7915-22.
86. Marui N, Offermann MK, Swerlick R et al. Vascular cell adhesion molecule (VCAM1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993;92:1866-74.
87. Yan SD, Schmidt AM, Anderson GM et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptor binding proteins. J Biol Chem 1994;269:9889-94.
88. O'Brien R, Trimmins K. The role of oxidation and glycation in the pathogenesis of diabetic atherosclerosis. Trends Endocrinol Metab 1994;5:329-34.
89. Zweier JL, Broderick R, Kuppusamy P, Thompson-Gorman S, Lutty GA. Determination of the mechanism of free radical generation in human aortic endothelial cells exposed to anoxia and reoxygenation. J Biol Chem 1994;269:24156-62.
90. Yan SD, Yan SF, Chen X et al. Non enzymatically glycated tau protein in Alzheimer's disease induce neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide. Nature Med 1995;1:693-9.
91. Monnier VM, Kohn RR, Cerami A. Accelerated age-related browning of human colagen in diabetes mellitus. Proc Natl Acad Sci USA 1994;81:583-7.
92. Nakamura Y, Hori Y, Nishino T et al. Immunohistochemical localization of AGEs in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993;143:1649-56.
93. Williamson JR, Chang K, Tilton RG et al. Increased vascular permeability in spontaneously diabetic BB/W rats and in rats with mild or severous severe streptozocin-induced diabetes. Prevention by aldose reductase inhibitors and castration. Diabetes 1987; 36:813-21.
94. Wautier JL, Zoukourian C, Chappey O et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: soluble receptor for advanced glycation endproducts blocks hyperpermeability in diabetic rats. J Clin Invest 1996;97:238-43.
95. Yaquob M, Patrick AW, McClelland P et al. Relationship between markers of endothelial dysfunction, oxidant injury and tubular damage in patients with insulin-dependent diabetes mellitus. Clin Sci 1993;85:557-62.
96. Aiello LP, Avery RL, Arrigg PG. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.
97. Yamagishi SI, Hsu Cheng-Chin, Taniguchi M et al. Receptor-mediated toxicity to pericytes of advanced glycosylation endproducts. Biochem Biophys Res Commun 1995;213:681-7.
98. Mandarino LJ. Current hypotheses for the biochemical basis of diabetic retinopathy. Diabetes Care 1992; 15:1892-901.
99. Beisswenger PJ, Morre LL, Brinck-Johnsen T, Curphey TJ. Increased collagen-liked pentosidine levels and AGEs in early diabetic nephropathy. J Clin Invest 1993;92:212-7.
100. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 1991; 88:11555-8.
101. Falk RJ, Scheinman JI, Mauer SM, Michael AF. Polyantigenic expansion of basement membrane constituents in diabetic nephropathy. Diabetes 1983;32:34-9.
102. Makita Z, Radoff S, Rayfeild EJ et al. Advanced glycation end products in patients with diabetic nephropathy. N Engl J Med 1991;325:836-42.
103. Yang CW, Vlassara H, Peten EP, He CJ, Striker CE, Striker LJ. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 1994;91:9436-40.
104. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycated end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci USA 1992;89:2873-7.
105. Wautier JL, Galacteros F, Wautier MP et al. Clinical manifestations and erythrocyte adhesion to endothelium in sickle cell syndrome. Am J Hematol 1985;121:19-26.
106. Raventos-Suarez C, Kaul DK, Mackuso F, Nagel RL. Membrane knobs are required for the microcirculatory obstruction induced by plasmodium falciparum-infected erythrocytes. Proc Natl Acad Sci USA 1985;82:3829-33.
107. Wautier JL, Leblanc, H, Wautier MP, Abadie E, Passa P, Caen J. Erythrocyte adhesion to cultured endothelium and glycaemic control in type 1 (insulin-dependent) diabetic patients. Diabetologia 1986;29:151-5.